Spinal Muscular Atrophy Medicine Market

Spinal Muscular Atrophy Medicine Market contains market size and forecasts of Spinal Muscular Atrophy Medicine in global, including the following market information:
Global Spinal Muscular Atrophy Medicine Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Spinal Muscular Atrophy Medicine Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Spinal Muscular Atrophy Medicine companies in 2021 (%)
The global Spinal Muscular Atrophy Medicine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
LMI-070 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Spinal Muscular Atrophy Medicine include Astellas Pharma Inc., AveXis, Inc., Bioblast Pharma Ltd., Cytokinetics, Inc. 24, F. Hoffmann-La Roche Ltd., Genethon, Genzyme Corporation, GMP-Orphan SAS and Ionis Pharmaceuticals, Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Spinal Muscular Atrophy Medicine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Spinal Muscular Atrophy Medicine Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Spinal Muscular Atrophy Medicine Market Segment Percentages, by Type, 2021 (%)
LMI-070
ND-602
NT-1654
Nusinersen
NXD-30001
Others
Global Spinal Muscular Atrophy Medicine Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Spinal Muscular Atrophy Medicine Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Others
Global Spinal Muscular Atrophy Medicine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Spinal Muscular Atrophy Medicine Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Spinal Muscular Atrophy Medicine revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Spinal Muscular Atrophy Medicine revenues share in global market, 2021 (%)
Key companies Spinal Muscular Atrophy Medicine sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Spinal Muscular Atrophy Medicine sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astellas Pharma Inc.
AveXis, Inc.
Bioblast Pharma Ltd.
Cytokinetics, Inc. 24
F. Hoffmann-La Roche Ltd.
Genethon
Genzyme Corporation
GMP-Orphan SAS
Ionis Pharmaceuticals, Inc.
Longevity Biotech, Inc
Neurodyn Inc.
Neurotune AG
Novartis AG
Sarepta Therapeutics, Inc.
Voyager Therapeutics, Inc.
Vybion, Inc.
WAVE Life Sciences Ltd.